| T1DM1 | T2DM2 |
Baseline characteristics | N = 26 | N = 80 |
Males, N (%) | 11 (42.3) | 37 (46.3) |
Age (years), mean (SD) | 36.5 (13.3) | 61.1 (10.9) |
Weight (kg), mean (SD) | 61.8 (15.9) | 63.3 (16.7) |
Hb1Ac (%), mean (SD) | 9.1 (2.3) | 9.0 (1.5) |
Duration of diabetes (years), mean (SD) | 14.6 (9.3) | 16.7 (7.8) |
Number of comorbidities, mean (SD) | 0.9 (1.0) | 2.2 (1.3) |
N(%) Hypertension Coronary Artery Disease Myocardial Infarction Congestive Heart Failure Stroke Peripheral Vascular Disease Dyslipidaemia Renal Impairment PCI/CABG Limp amputation Dialysis/transplant, |
8 (30.8) 2 (7.7) 1 (3.8) 0 (0.0) 1 (3.8) 0 (0.0) 12 (46.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) |
63 (78.8) 12 (15.0) 2 (2.5) 3 (3.8) 6 (7.5) 2 (2.5) 65 (81.3) 11 (13.8) 9 (11.3) 1 (1.3) 1 (1.3) |
OAD3s prescribed prior to commencing insulin, mean (SD) | 0.1 (0.4) | 2.2 (0.9) |
Patients reporting prior hypoglycaemia, N (%) | 18 (69.2) | 21 (26.3) |
Prior treatment regimens, N (%) | N = 26 | N = 80 |
Insulin naïve | 5 (19.2) | 48 (60.0) |
OAD | 2 (7.7) | 76 (95.0) |
NPH4 | 3 (11.5) | 17 (21.3) |
Basal bolus | 16 (61.5) | 7 (8.8) |
Premixed | 3 (11.5) | 8 (10.0) |
Reasons to switch to glargine, N(%) | N = 26 | N = 80 |
Hypoglycaemia | 13 (50.0) | 14 (17.5) |
Uncontrolled HbA1c5 | 12 (46.2) | 65 (81.3) |
Convenience | 1 (3.8) | 0 (-) |
Others | 0 (-) | 1 (0.0) |